• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Renalytix plc (Amendment)

    2/14/23 6:10:09 AM ET
    $RNLX
    Medical Specialities
    Health Care
    Get the next $RNLX alert in real time by email
    SC 13G/A 1 tm236326d9_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (RULE 13d - 102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2

     

    (Amendment No. 2)*

     

    Renalytix plc

    (Name of Issuer)

     

    Ordinary Shares, £0.0025 par value per share

    (Title of Class of Securities)

     

    75973T101

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Page 1 of 5 Pages)

     

     

     

     
    Page 2 of 5

    CUSIP No. 75973T101

     

    1

    NAME OF REPORTING PERSON

     

    Gilder, Gagnon, Howe & Co. LLC 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York 




    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    0 

    6

    SHARED VOTING POWER

     

    0 

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,009,083 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     
    1,009,083

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 

     

    2.7%

    12

    TYPE OF REPORTING PERSON

     

    BD 

      

     
    Page 3 of 5

     

    ITEM 1(a).Name of Issuer:

     

    Renalytix plc

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    Finsgate

    5-7 Cranwood Street

    London EC1V 9EE

    United Kingdom

     

    Item 2(a).Name of Persons Filing:

     

    Gilder, Gagnon, Howe & Co. LLC

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    475 10th Avenue

    New York, NY 10018

     

    Item 2(c).Citizenship:

     

    New York

     

    Item 2(d).Title of Class of Securities

     

    Ordinary Shares

     

    Item 2(e).CUSIP Number:

     

    75973T101

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    (a) x Broker or dealer registered under Section 15 of the  Act (15 U.S.C. 78o).
    (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) o Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8).
    (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
    (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
    (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
    (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
    (j) o A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J)
    (k) o Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     
    Page 4 of 5

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

      

    (a)Amount beneficially owned: 1,009,083

     

    (b)Percent of class: 2.7%

     

    (c)Number of Shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: 0

     

    (ii)Shared power to vote or direct the vote: 0

     

    (iii)Sole power to dispose or direct the disposition: 0

     

    (iv)Shared power to dispose or direct the disposition: 1,009,083

     

    The shares reported include 1,009,083 shares held in customer accounts over which partners and/or employees of the Reporting Person have discretionary authority to dispose of or direct the disposition of the shares.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.

     

     
    Page 5 of 5

     

    SIGNATURES

     

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

     

    Dated: February 14, 2023 

     

      GILDER, GAGNON, HOWE & CO. LLC  
           
           
      By:  /s/ Laura Esposito  
      Name: Laura Esposito  
      Title: Chief Compliance Officer  

      

     

     

    Get the next $RNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNLX

    DatePrice TargetRatingAnalyst
    1/18/2022$30.00Buy
    HC Wainwright & Co.
    1/4/2022$24.00Buy
    BTIG
    10/4/2021$28.00Buy
    Guggenheim
    7/2/2021$38.00Buy
    Berenberg
    More analyst ratings

    $RNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

      LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran's primary responsibility will be leading the KidneyIntelX global sales effort. He is a senior executive with over 30 years of diversified general management, strategic planning, and marketing/sales experience in the diagnostics and pharmaceutical industries in domestic and international markets. Mr. Doran serv

      9/7/23 7:00:27 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

      LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP ("Deloitte") in 2020, where she was a senior partner and served as one of Deloitte's life sciences

      7/3/23 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

      PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc

      5/12/22 1:00:00 PM ET
      $AERC
      $NVCR
      $PODD
      $RNLX
      Environmental Services
      Utilities
      Medical/Dental Instruments
      Health Care

    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Renalytix with a new price target

      HC Wainwright & Co. initiated coverage of Renalytix with a rating of Buy and set a new price target of $30.00

      1/18/22 6:09:55 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • BTIG initiated coverage on Renalytix with a new price target

      BTIG initiated coverage of Renalytix with a rating of Buy and set a new price target of $24.00

      1/4/22 6:53:29 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Guggenheim initiated coverage on Renalytix with a new price target

      Guggenheim initiated coverage of Renalytix with a rating of Buy and set a new price target of $28.00

      10/4/21 8:16:45 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Financials

    Live finance-specific insights

    See more
    • Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

      LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration ("FDA") De Novo authorized kidneyintelX.dkd, and release of new real

      5/15/24 7:00:14 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

      LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to joi

      5/9/24 7:00:12 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

      LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events. The Company made significant progress during the quarter in revenue generation, reimbursement coverage, the publication of real-world evidence

      2/15/24 7:00:32 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    SEC Filings

    See more

    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form DEF 14A filed by Renalytix plc

      DEF 14A - Renalytix plc (0001811115) (Filer)

      10/11/24 4:36:26 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by Renalytix plc

      PRE 14A - Renalytix plc (0001811115) (Filer)

      10/1/24 5:14:50 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix plc filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Renalytix plc (0001811115) (Filer)

      10/1/24 5:12:55 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Commencement of trading on OTCQB in the United States

      LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., that effective with the market open today its ADSs are now trading on the OTCQB. The Directors have considered the benefits of the Nasdaq listing against the cost of maintaining the listing and have decided to downlist the ADSs from Nasdaq, and a

      10/8/24 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

      LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will in

      7/11/24 7:00:03 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

      LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Comp

      6/27/24 6:30:18 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renalytix plc

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      10/2/24 8:05:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Renalytix plc (Amendment)

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      4/26/24 4:01:17 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Renalytix plc

      SC 13G - Renalytix plc (0001811115) (Subject)

      4/4/24 10:15:51 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Interim Chief Financial Office Jung Joel R

      4 - Renalytix plc (0001811115) (Issuer)

      6/13/24 4:15:05 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Jung Joel R

      3 - Renalytix plc (0001811115) (Issuer)

      6/5/24 4:17:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Icahn School Of Medicine At Mount Sinai acquired $2,340,094 worth of Ordinary Shares (9,360,374 units at $0.25) (SEC Form 4)

      4 - Renalytix plc (0001811115) (Issuer)

      4/26/24 4:01:47 PM ET
      $RNLX
      Medical Specialities
      Health Care